Oncology + Obesity

TNIK

CHEMBL4527

PAUSED

33,755 ADMET-validated (in-silico) FIC candidates. Tanimoto < 0.21 vs rentosertib (FTO-clean white-space library). Program paused pending prioritization of data-rich kinases.

데이터 무결성 / Data-lineage: TNIK is currently deprioritized in favor of our data-rich validated kinases. The counts below are in-silico only — no TNIK compound has been wet-lab validated. (ChEMBL display corrected to CHEMBL4527; the daemon/data always used the correct target.)

ADMET Passed

33,755

Pareto Rank-1 Count

1,847

CRO

On hold

Stage

Deprioritized — data-rich focus

Pareto Rank-1 is a front-membership count, not a quality ranking — the front is near-saturated, so it does not discriminate quality. Meaningful selection uses consensus + wet-lab.

Mechanism

TRAF2/NCK-interacting kinase (TNIK) inhibition — Wnt signaling downstream node

Precedent

No approved drug. Rentosertib (Insilico, Phase II NCT05938920) is sole clinical-stage competitor.

Indications

Colorectal cancer · Obesity · Idiopathic pulmonary fibrosis

Milestones

2026-W10

FIC library reached 33,755 compounds — largest FIC TNIK library known

2026-W13

Exploratory CRO round run (results private per policy)

2026-W17

Program deprioritized in favor of data-rich validated kinases

Dashboard →Browse compounds →Methodology →